Clinical and paraclinical characteristics of chronic myeloproliferative neoplasms Philadelphia chromosome negative

  • Julio César Lozano Fundación Universitaria de Ciencias de la Salud
  • Claudia Patricia Casas Fundación Universitaria de Ciencias de la Salud
  • Viriginia Abello Fundación Universitaria de Ciencias de la Salud
  • Maria Helena Solano Fundación Universitaria de Ciencias de la Salud

Abstract

Objective: describe features clinics and patients with chronic myeloproliferative neoplasm chromosome Philadelphia negative valued at the Hospital San Jose hematology outpatient from January 2005 until May 2010. Materials and methods: Studio series case included patients diagnosed with chronic myeloproliferative neoplasm chromosome Philadelphia negative. Results: A total of 34 chronic myeloproliferative neoplasm chromosome Philadelphia negative patients were identified. The main found diagnosis was Essential Thrombocythemia in 17 patients (50%), Polycythemia Rubra Vera in six patients (17.6%), chronic myeloproliferative neoplasm associated with eosinophilia in six patients (17.6%), myelofibrosis primary in three patients (8.8%) and chronic myeloproliferative neoplasm not classifiable in two patients (5.8%). The median age was 63.5 years (R: 51-74) and 21 patients (61.7%) were female. Two patients in the total number progressed Myelofibrosis (5.8%), no patient acute leukemia development. Twenty-seven patients (79.4%) received Hydroxyurea as main pharmacological management. Fourteen patients presented complications (41.1%), of which five were thrombotic episodes (14.7%), three bleeding episodes (8.8%), three patients had pulmonary hypertension (8.8%) and one patient developed Vertigo (2.9%). Finally the time since diagnosis until the occurrence of complications was 19.55 months (R: 8-50.23). Conclusion: neoplasm Mieloproliferativas Chronicles are very rare pathologies, as many are grouped into essential Thrombocythemia, Polycythemia Vera and neoplasms associated with Eosinophilia. The main therapeutic option is with a low toxicity Hydroxyurea. It is not possible to analyze the presence of mutations tyrosine kinases (JAK2 V617F PGDFRA PDGFRB, FGFR1) because they are tools of recent entry to the diagnostic arsenal and whose impact as a prognostic factor or therapeutic is in studio. Thrombotic venous events are frequently found in these patients

Metrics

Metrics Loading ...
Published
2015-04-27
How to Cite
Lozano, J. C., Casas, C. P., Abello, V., & Solano, M. H. (2015). Clinical and paraclinical characteristics of chronic myeloproliferative neoplasms Philadelphia chromosome negative. Acta Medica Colombiana, 37(2), 66-73. https://doi.org/10.36104/amc.2012.599
Section
Original works